Related Experiment Video
Updated: Aug 15, 2026
Depletion and Reconstitution of Macrophages in Mice
Published on: August 1, 2012
Muramyl dipeptide improves mononuclear phagocyte system function in obstructive jaundice
1Department of Surgery, University of Texas Southwestern Medical Center, Dallas 75235-9031.
Abstract:
Previous studies have demonstrated depression of the mononuclear phagocyte system (MPS) of which the liver comprises 80-85% in animals subjected to 21 days of obstructive jaundice. This study examined the ability of a macrophage stimulant, muramyl dipeptide (MDP), to reverse MPS dysfunction in an obstructive jaundice rat model. Sixty-two male Sprague-Dawley rats underwent sham (n = 29) laparotomy or common duct ligation (CDL) (n = 33) and were studied after 21 days. Animals were injected with 1-3.5 X 10(6) Escherichia coli via a lateral tail vein, and colony-forming units (CFU) of the liver, lung, and spleen were determined at two time intervals: 30 min postinjection to determine the phagocytic activity of MPS (sham, n = 16; CDL, n = 20) and 24 hr postinjection to determine cytotoxic activity of MPS (sham, n = 13; CDL, n = 13). MDP (3 micrograms/g) was administered subcutaneously 24 hr prior to E. coli injection in 6 sham and 10 CDL rats studied at the 30-min time interval and 7 sham and 7 CDL rats studied at the 24-hr time interval. Pretreatment with MDP appeared to reverse the impairment of phagocytic activity in the liver of CDL rats returning it to the level of sham animals (P less than 0.05). However, pretreatment with MDP did not enhance the cytotoxic activity of the MPS as evidenced by higher CFU of E. coli in the liver, lung, and spleen of CDL animals pretreated with MDP as compared to CDL animals that did not receive MDP pretreatment. This increase was only significant in the spleen.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Muramyl dipeptide (MDP) reversed impaired liver phagocytic activity in obstructive jaundice rats but did not improve overall macrophage cytotoxic function. This suggests MDP may partially restore mononuclear phagocyte system (MPS) function in liver disease.
Area of Science:
- Immunology
- Hepatology
- Sepsis Research
Background:
- Obstructive jaundice leads to significant dysfunction of the mononuclear phagocyte system (MPS), particularly in the liver.
- The MPS plays a crucial role in clearing bacterial infections, and its impairment can increase susceptibility to sepsis.
Purpose of the Study:
- To investigate the efficacy of muramyl dipeptide (MDP), a macrophage stimulant, in reversing MPS dysfunction in a rat model of obstructive jaundice.
- To assess the impact of MDP on both phagocytic and cytotoxic activities of the MPS.
Main Methods:
- Male Sprague-Dawley rats underwent common duct ligation (CDL) or sham surgery, with studies conducted after 21 days.
- Escherichia coli was injected intravenously to assess MPS function, measuring colony-forming units (CFU) in the liver, lung, and spleen at 30 minutes (phagocytic activity) and 24 hours (cytotoxic activity).
- Rats were pretreated with MDP (3 µg/g) subcutaneously 24 hours prior to E. coli injection.
Main Results:
- MDP pretreatment significantly reversed the depression of hepatic phagocytic activity in CDL rats, restoring it to sham levels (P < 0.05).
- MDP did not enhance the cytotoxic activity of the MPS in CDL rats, as evidenced by similar or increased E. coli CFU in the liver, lung, and spleen compared to non-MDP treated CDL rats.
- A significant increase in splenic CFU was observed in MDP-treated CDL rats compared to untreated CDL rats, indicating a potential localized effect.
Conclusions:
- Muramyl dipeptide (MDP) can partially restore impaired phagocytic function of the liver's mononuclear phagocyte system (MPS) in obstructive jaundice.
- MDP does not appear to improve the cytotoxic capacity of the MPS in this model, suggesting a selective effect on macrophage function.
- Further research is warranted to explore the therapeutic potential of MDP in managing MPS dysfunction associated with liver diseases.
